BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31598934)

  • 1. [Analysis of mutations of 14 genes among 87 patients with myelodysplastic syndrome].
    Zhou X; Jin H; Mu Q; Sheng L; Lai B; Zhu H; Ouyang G
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Oct; 36(10):953-956. PubMed ID: 31598934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
    Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
    [No Abstract]   [Full Text] [Related]  

  • 3. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
    Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
    Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Characteristics and Karyotype Analysis of Myelodysplastic Syndrome Patients with TP53 mutation].
    Zhou XY; Ouyang GF; Mu QT; Sheng LX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):872-876. PubMed ID: 31204947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics and Clinical Significance of Gene Mutation in Patients with Myelodysplastic Syndrome].
    Zhao F; Wang KL; Qin YT; Nilupar T; Patiguli A; Jiang M; Hao JP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1864-1868. PubMed ID: 34893124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
    Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.
    Tefferi A; Lasho TL; Patnaik MM; Saeed L; Mudireddy M; Idossa D; Finke C; Ketterling RP; Pardanani A; Gangat N
    Am J Hematol; 2017 Dec; 92(12):1311-1317. PubMed ID: 28875545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
    Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.
    Nazha A; Bejar R
    Curr Hematol Malig Rep; 2017 Oct; 12(5):461-467. PubMed ID: 28844082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome.
    Ren Y; Lang W; Mei C; Luo Y; Ye L; Wang L; Zhou X; Xu G; Ma L; Jin J; Tong H
    Hematol Oncol; 2023 Feb; 41(1):159-166. PubMed ID: 36316121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
    Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
    Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
    Falantes JF; Márquez-Malaver FJ; Carrillo E; Culebras MG; Morales R; Prats C; Vargas MT; Caballero T; Rodríguez-Arbolí E; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1059-e1066. PubMed ID: 36117041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
    Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
    Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
    Gu S; Xia J; Tian Y; Zi J; Ge Z
    BMC Cancer; 2021 Feb; 21(1):134. PubMed ID: 33549060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes].
    Huang HJ; Li B; Qin TJ; Xu ZF; Hu NB; Pan LJ; Qu SQ; Liu D; Zhang YD; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):723-730. PubMed ID: 33113603
    [No Abstract]   [Full Text] [Related]  

  • 17. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
    Loghavi S; Al-Ibraheemi A; Zuo Z; Garcia-Manero G; Yabe M; Wang SA; Kantarjian HM; Yin CC; Miranda RN; Luthra R; Medeiros LJ; Bueso-Ramos CE; Khoury JD
    Br J Haematol; 2015 Oct; 171(1):91-9. PubMed ID: 26123119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes.
    Maurya N; Mohanty P; Dhangar S; Panchal P; Jijina F; Mathan SLP; Shanmukhaiah C; Madkaikar M; Vundinti BR
    Sci Rep; 2022 Apr; 12(1):5925. PubMed ID: 35396491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.
    Melody M; Al Ali N; Zhang L; Ramadan H; Padron E; Sallman D; Sweet K; Lancet J; List A; Bennett JM; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):324-328. PubMed ID: 32044274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
    Montalban-Bravo G; Kanagal-Shamanna R; Benton CB; Class CA; Chien KS; Sasaki K; Naqvi K; Alvarado Y; Kadia TM; Ravandi F; Daver N; Takahashi K; Jabbour E; Borthakur G; Pemmaraju N; Konopleva M; Soltysiak KA; Pierce SR; Bueso-Ramos CE; Patel KP; Kantarjian H; Garcia-Manero G
    Blood Adv; 2020 Feb; 4(3):482-495. PubMed ID: 32027746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.